PFO
AXDX

Pathstone Family Office’s Accelerate Diagnostics AXDX Stock Holding History

Pathstone Family Office’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12
Closed -$3K – 649
2019
Q1 		$3K Buy
+12
New +$2.25K ﹤0.01% 671

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Pathstone Family Office's AXDX Position: Q2 2019 in Review

Pathstone Family Office sold out of Accelerate Diagnostics (AXDX) in Q2 2019, closing a stake of 12 shares — an estimated $3K sold.

Pathstone Family Office first reported a position in AXDX in Q1 2019 and held it in 1 quarter. The position peaked at $3K in Q1 2019. 117 funds tracked by Wall St. Rank hold AXDX as of Q2 2019.

  • Pathstone Family Office reported no remaining Accelerate Diagnostics position as of Q2 2019 after selling out during the quarter.
  • Pathstone Family Office sold 12 Accelerate Diagnostics shares in Q2 2019, an estimated $3K.
  • Pathstone Family Office first reported a position in Accelerate Diagnostics in Q1 2019 and held it in 1 quarter.
  • Pathstone Family Office's Accelerate Diagnostics position peaked at $3K in Q1 2019.
  • 117 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2019.

Based on Pathstone Family Office's 13F filing for Q2 2019, filed 14 Aug 2019.